Signal Sequence (e.g., Beta-galactosidase, Etc.) Patents (Class 435/69.8)
-
Patent number: 6284726Abstract: Peptide analogs of the high molecular weight kininogen domain 5 are potent inhibitors of angiogenesis. The peptides have the formula X1-(HGLGHGHEQQHGKGH)-X2 (I) wherein X1 is from zero to 25 amino acids; X2 is from zero to 60 amino acids. Methods of inhibiting endothelial cell proliferation and angiogenesis are provided.Type: GrantFiled: July 7, 2000Date of Patent: September 4, 2001Assignees: Temple University - Of The Commonwealth System of Higher Education, Du Pont Pharmaceuticals CompanyInventors: Robert W. Colman, Shaker A. Mousa
-
Patent number: 6280976Abstract: The present invention relates to isolated nucleic acid sequences encoding polypeptides having cellobiose dehydrogenase activity. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid sequences as well as recombinant methods for producing the polypeptides.Type: GrantFiled: January 5, 2000Date of Patent: August 28, 2001Assignee: Novozymes Biotech, Inc.Inventors: Elizabeth J. Golightly, Kimberly M. Brown
-
Patent number: 6277631Abstract: Recombinant yeast expression vectors with the features indicated in the patent claims are described. These recombinant yeast expression vectors can be used for the preparation of HBeAg in yeast host organisms. Appropriate expression systems, transformed host organisms, diagnostic aids and medicinal agents are additionally described.Type: GrantFiled: May 22, 1995Date of Patent: August 21, 2001Assignee: Dade Behring Marburg GmbHInventors: Michael Noah, Michael Bröker
-
Patent number: 6274345Abstract: The present invention relates to expression vectors containing a gene encoding outer membrane protein C(OmpC) from Escherichia coli as a cell surface anchoring motif, more specifically, to expression vectors comprising a gene encoding OmpC which is designed to express a gene of foreign protein in fused form with OmpC on the cell surface of Escherichia coli, and a method for displaying the desired protein on the surface of the bacteria employing the OmpC as a cell surface anchoring motif. In accordance with the present invention, the desired protein can be expressed efficiently on the cell surface of bacteria so that the expressed protein can be applied to a variety of applications such as live vaccine development, peptide libraries screening, antibody production, environmental bioadsorbent, whole cell catalysis, and biosensor development.Type: GrantFiled: February 18, 2000Date of Patent: August 14, 2001Assignee: Korea Advanced Institute of Science and TechnologyInventors: Sang Yup Lee, Zhaohui Xu, Jong Hyun Choi
-
Patent number: 6270960Abstract: The present invention concerns a polypeptide which is composed of the amino acids 1207±10 to 1488±10 of a hepatitis C virus and of less than 20 foreign amino acids and the use of this polypeptide as an antigen in an immunological test.Type: GrantFiled: June 12, 2000Date of Patent: August 7, 2001Assignee: Roche Diagnostics GmbHInventors: Christoph Seidel, Ursula-Henrike Wienhues, Urban Schmitt, Manfred Motz, Michael Wiedmann, Barbara Upmeier, Erwin Soutschek
-
Patent number: 6268171Abstract: The invention relates to recombinant gene sequences for synthesizing a protein having the biological activity of the PilC protein. Furthermore, the invention relates to DNA recombinant methods for the production of proteins having the biological activity of the PilC protein as well as the tools of molecular biology needed therein. Besides, the invention relates to proteins having the biological activity of the PilC protein and its antibodies. Further embodiments of the invention are pharmaceutical compositions with a content of the mentioned proteins or antibodies. Preferably, these pharmaceutical compositions serve as vaccines for the immunization against pathogenic bacteria bearing type 4 pili. The invention also relates to kits for the detection of bacteria bearing type 4 pili or antibodies directed against them containing the mentioned proteins or antibodies. Finally, the invention relates to cellular receptors for bacteria bearing type 4 pili and analogues thereof.Type: GrantFiled: June 28, 1996Date of Patent: July 31, 2001Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Thomas Franz Ferdinand Meyer, Thomas Rudel, Roland Richard Ryll, Ina Bärbel Scheuerpflug
-
Patent number: 6258563Abstract: The present invention relates to secretion in Gram-positive microorganisms. The present invention provides the nucleic acid amino acid sequences for the Bacillus subtilis secretion factors SecDF. The present invention also provides improved methods for the secretion of heterologous or homologous proteins in gram-positive microorganisms.Type: GrantFiled: March 22, 2000Date of Patent: July 10, 2001Assignee: Genencor International, Inc.Inventor: Wilhelmus J. Quax
-
Patent number: 6258530Abstract: A composition of matter comprising a plurality of procaryotic cells containing a diverse population of expressible oligonucleotides operationally linked to expression elements, said expressible oligonucleotides having a desirable bias of random codon sequences.Type: GrantFiled: December 30, 1994Date of Patent: July 10, 2001Assignee: Ixsys, INC.Inventor: William D. Huse
-
Patent number: 6258787Abstract: The present invention provides a method for inducing reendothelialization of the lining of an injured blood vessel comprising contacting the injured portion of the vessel with nucleic acid encoding an endothelial cell mitogen operably linked to a promoter (nucleic acid cassette) to result in expression of the mitogen when delivered to the cells at the site of vascular injury. The resulting reendothelialization of the injured blood vessel inhibits smooth muscle cell proliferation and consequently reduces restenosis. The methods of the present invention may be used to treat any blood vessel injury that results in denuding of the endothelial lining of the vessel wall, including, for example, those injuries resulting from balloon angioplasty and deployment of endovascular stents.Type: GrantFiled: July 30, 1997Date of Patent: July 10, 2001Assignee: St. Elizabeth's Medical Center of Boston, Inc.Inventor: Jeffrey M. Isner
-
Patent number: 6255562Abstract: The present invention relates to a process for preparing recombinantly modified, inulin-producing plants, to the DNA sequences which are used in this context and to the transformed plants which are obtained.Type: GrantFiled: November 3, 1998Date of Patent: July 3, 2001Assignees: Sudzucker Aktiengesellschaft, KWS Saat AGInventors: Arnd G. Heyer, Regina Wendenburg
-
Patent number: 6245532Abstract: A method of preparing a recombinant influenza vaccine using DNA technology is provided. The resulting vaccine is a multivalent, preferably trivalent, influenza vaccine based on a mixture of recombinant hemagglutinin antigens cloned from influenza viruses having epidemic potential. The recombinant hemagglutinin antigens are full length, uncleaved (HA0), glycoproteins produced from baculovirus expression vectors in cultured insect cells and purified under non-denaturing conditions. The recombinant vaccine can be developed from primary sources of influenza, for example, nasal secretions from infected individuals, rather than from virus adapted to and cultured in chicken eggs. The process for cloning influenza hemagglutinin genes from influenza A and B viruses uses specially designed oligonucleotide probes and PCR. In the preferred embodiment, the cloned HA genes are then modified by deletion of the natural hydrophobic signal peptide sequences and replacing them with a new baculovirus signal peptide.Type: GrantFiled: October 9, 1998Date of Patent: June 12, 2001Assignee: Protein Sciences CorporationInventors: Gale E. Smith, Franklin Volvovitz, Bethanie E. Wilkinson, Andrei I. Voznesensky, Craig S. Hackett
-
Patent number: 6235530Abstract: The present invention provides a DNA sequence encoding an oxalate oxidase. The oxalate oxidase may be used for the resistance of plants to diseases caused by Sclerotinia sp. It may be provided by a chimeric gene and a vector containing the coding sequence. It may be used to confer on plants an increased resistance to diseases caused by Sclerotinia sp.Type: GrantFiled: May 23, 1995Date of Patent: May 22, 2001Assignee: Rhone-Poulenc AgrochimieInventors: Georges Freyssinet, Alain Sailland
-
Patent number: 6229065Abstract: The present invention provides a DNA sequence encoding an oxalate oxidase. The oxalate oxydase may be used for the resistance of plants to diseases caused by Sclerotinia sp. It may be provided by a chimeric gene and a vector containing the coding sequence. It may be used to confer on plants an increased resistance to diseases caused by Sclerotinia sp.Type: GrantFiled: March 6, 1995Date of Patent: May 8, 2001Assignee: Rhone-Poulenc AgrochimieInventors: Georges Freyssinet, Alain Sailland
-
Patent number: 6222095Abstract: The present invention provides isolated nucleic acid molecules comprising a polynucleotide sequence encoding a primary auxin response protein degradation signal linked to a heterologous eukaryotic polynucleotide sequence encoding a target polypeptide. Also provided are transgenic plants comprising an expression cassette comprising a polynucleotides of the invention. The invention further provides methods of targeting a recombinantly expressed target polypeptide in a plant for degradation.Type: GrantFiled: April 22, 1998Date of Patent: April 24, 2001Assignee: The Regents of the University of CaliforniaInventors: Judy Callis, Cathy K. Worley
-
Patent number: 6215051Abstract: The present invention is directed to a method for the production of a transgenic plant of rice crop comprising the steps of infecting an immature embryo of rice crop with the genus Agrobacterium for transformation; co-culturing the infected embryo with a dicot suspension culture during the step of transformation; allowing the transformed embryo to grow into a callus in a selective medium comprising a sufficient amount of a plant growth hormone for the growth of rice crop; and allowing the cultured callus to regenerate root and shoot in a regeneration medium comprising a pre-determined amount of nutrients for the growth of rice crop. The invention is further directed to a transformed rice plant made by methods of this invention.Type: GrantFiled: May 4, 1998Date of Patent: April 10, 2001Assignee: National Science Council of R.O.C.Inventors: Su-May Yu, Li-Fei Liu, Ming-Tsair Chan
-
Patent number: 6211435Abstract: The present invention provides polynucleotides and related polypeptides of the enzyme APAO isolated from Exophiala spinifera. Additionally, the polynucleotide encoding for the APAO enzyme can be used to transform plant cells normally susceptible to Fusarium or other toxin-producing fungus infection. Plants can be regenerated from the transformed plant cells. Additionally, the present invention provides for expressing both APAO and a fumonisin esterase in a transgenic plant. In this way, a transgenic plant can be produced with the capability of degrading fumonisin, as well as with the capability of producing the degrading enzymes. In addition, the present invention provides methods for producing the APAO enzyme in both prokaryotic and non-plant eukaryotic systems. Methods for detoxification in grain, grain processing, silage, food crops and in animal feed and rumen microbes are also disclosed.Type: GrantFiled: July 12, 1999Date of Patent: April 3, 2001Assignees: Pioneer Hi-Bred International, Inc., CuraGen CorporationInventors: Jonathan P. Duvick, Jacob T. Gilliam, Joyce R. Maddox, Oswald R. Crasta, Otto Folkerts
-
Patent number: 6194169Abstract: Enhanced yields of the platelet-derived growth factor (PDGF) B-chain are obtained using the Pichia pastoris yeast system. Yields of both wild-type and mutant human proteins are enhanced when the yeast is transformed with a vector containing the yeast mating factor promoter fused to a sequence encoding the mature protein. The secreted wild-type protein is indistinguishable from mature 29-32 kDa protein isolated from human and Chinese hamster ovary (CHO) cells. An RKK→EEE mutant exhibited reduced association with the cell surface and accumulated in the culture medium as 29-32 kDa forms. Stable transfection of U87 astrocytoma cells with RKK→EEE mutants of either the A- or B-chain inhibited malignant growth in athymic nude mice. Despite altered receptor binding activities, each mutant retained full mitogenic activity when applied to cultured Swiss 3T3 cells. Circular dichroism spectrophotometric analysis of the RKK→EEE mutant revealed a secondary structure indistinguishable from the wild type.Type: GrantFiled: June 4, 1998Date of Patent: February 27, 2001Assignee: The University of Kentucky Research FoundationInventor: David M. Kaetzel
-
Patent number: 6190906Abstract: The invention provides an expression vector useful in expressing foreign genes in procaryotes. The vector consists of the promotor/operator region and initiation point of translation of the mg1 operon. This combination is referred to as a regulation sequence. In order to prepare this, desired portions of the mg1 operon are cut from the genome of a cell which can utilize galactose via appropriate restriction endonucleases. This is then inserted into a DNA vector.Type: GrantFiled: January 23, 1989Date of Patent: February 20, 2001Assignee: Roche Diagnostics GmbHInventors: Günther Schumacher, Michael Jarsch, Winfried Boos
-
Patent number: 6190885Abstract: A fusion protein comprises a sequence of amino acids which binds antibodies specific to the human milk fat globule (HMFG) differentiation antigens. Specific amino acid sequences are provided, and a fusion protein may be used as an immunogen and for diagnostic purposes.Type: GrantFiled: October 8, 1993Date of Patent: February 20, 2001Assignee: Cancer Research Fund of Contra CostaInventors: Roberto L. Ceriani, Jerry A. Peterson, David J. Larocca
-
Patent number: 6184440Abstract: The present invention discloses genetically engineered plants which display altered structure or morphology. The transgenic plants express a cell wall modulation transgene or gene construct that results in the altered structure or morphology. The altered structure or Morphology can be associated with, for example, altered biomass, growth, yield, greater or less resistance to biodegradation, more or less digestible to ruminants, altered cellulose content, larger leaves/normal hypocotyls or smaller leaves/longer hypocotyls, etc. compared to a non-transgenic plant of the same species. The cell wall modulation transgene can be any cellulose binding domain, a cellulose binding protein, or a cell wall modifying protein or enzyme such as endoxyloglucan transferase, xyloglucan endo-transglycosylase, an expansin, cellulose synthase, or a novel isolated endo-1,4-&bgr;-glucanase of Arabidopsis thaliana.Type: GrantFiled: January 13, 1998Date of Patent: February 6, 2001Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Oded Shoseyov, Ziv Shani, Etai Shpigel
-
Patent number: 6174701Abstract: A novel polypeptide, designated neuronal factor (NF), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NF useful in diagnostics and in the recombinant preparation of NF. NF is used in the treatment of nerve cells and in diagnostic assays.Type: GrantFiled: May 31, 1995Date of Patent: January 16, 2001Assignee: Genentech, Inc.Inventors: Arnon Rosenthal, John W. Winslow
-
Patent number: 6171817Abstract: Novel vectors are disclosed for expressing and secreting heterologous polypeptides from filamentous fungi. Such vectors are used in novel processes to express and secrete such heterologous polypeptides. The vectors used for transforming a filamentous fungus to express and secrete a heterologous polypeptide include a DNA sequence encoding a heterologous polypeptide and a DNA sequence encoding a signal sequence which is functional in a secretory system in a given filamentous fungus and which is operably linked to the sequence encoding the heterologous polypeptide. Such signal sequences may be the signal sequence normally associated with the heterologous polypeptides or may be derived from other sources. The vector may also contain DNA sequences encoding a promoter sequence which is functionally recognized by the filamentous fungus and which is operably linked to the DNA sequence encoding the signal sequence.Type: GrantFiled: November 24, 1997Date of Patent: January 9, 2001Assignee: Genencor International, Inc.Inventors: Randy Michael Berka, Daniel Cullen, Gregory Lawrence Gray, Kirk James Hayenga, Virgil Bryan Lawlis
-
Patent number: RE37343Abstract: A yeast &agr;-factor expression system is provided comprised of a truncated leader sequence, containing the &agr;-factor signal peptide and one glycosylation site, linked by a processing site to a non-yeast protein-encoding sequence.Type: GrantFiled: August 27, 1998Date of Patent: August 28, 2001Assignee: Chiron CorporationInventor: Patricia Tekamp-Olson